{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:01:19Z","timestamp":1768550479284,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapy of hepatitis C has been revolutionized by Direct Antiviral Agents. These drugs are safe and efficacious in all infected patients, including those with advanced, or decompensated cirrhosis, and are currently largely used in such cases in clinical practice worldwide. It was therefore cause of great concern the publication of two reports suggesting that treatment with <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s could increase the risk of hepatocellular carcinoma in cirrhotic patients, particularly in those receiving antiviral therapy after having been cured for an <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content>. These reports have generated a great and controversial debate and have been followed by a series of other publications not confirming such increased risk. This article summarizes published studies assessing the relation between <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> therapy and <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> in two different clinical setting: <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> recurrence in patients with an history of cured <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> and \u201cde novo\u201d <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> occurrence in patients without previous <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content>. Rates of <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> recurrence after <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s were extremely variable in different studies, reflecting great heterogeneity of this clinical setting. Data on \u201cde novo\u201d <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> incidence were more homogeneous and suggest that treatment with <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s is not modifying the risk of developing <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> in the first 6\u201012\u00a0months. The possibility that treatment with <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s may favour tumour growth and spread in individual patients with active <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> foci is suggested by some observations but remains unproven. There is clearly a need for prospective studies designed to better define these issues.<\/jats:p>","DOI":"10.1111\/liv.13390","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T08:45:15Z","timestamp":1496133915000},"page":"802-808","source":"Crossref","is-referenced-by-count":35,"title":["Increased incidence of liver cancer after successful <scp>DAA<\/scp> treatment of chronic hepatitis C: Fact or fiction?"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9926-2382","authenticated-orcid":false,"given":"Alfredo","family":"Alberti","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine University of Padova  Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Piovesan","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine University of Padova  Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.003"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13071"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27766"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.034"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.017"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00052-9"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.033"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.045"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.016"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.019"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13357"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13821"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.014"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28535"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.009"},{"issue":"1","key":"e_1_2_8_20_1","first-page":"10A","article-title":"Incidence and pattern of \u201cde novo\u201d hepatocellular carcinoma in HCV patients treated with oral DAAs","volume":"64","author":"Romano A","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21176"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.020263"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.140"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.027"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.023"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13390","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T21:27:49Z","timestamp":1695504469000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,24]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/liv.13390"],"URL":"https:\/\/doi.org\/10.1111\/liv.13390","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,24]]}}}